Drug intelligence / Profile preview

naphazoline + pheniramine + panthenol

Development stage
Unknown
Lead developer
EMS
Modality
Small Molecules
Administration
Intranasal, Ophthalmic
01

Overview

A fixed-dose combination of the sympathomimetic vasoconstrictor **naphazoline**, the first-generation antihistamine **pheniramine**, and the vitamin B5 analog **panthenol**. - **Naphazoline** acts as an alpha-adrenergic agonist that induces vasoconstriction, thereby reducing discomfort and redness in the nasal mucosa or conjunctival tissues. - **Pheniramine** blocks histamine H1-receptors, reducing allergy-mediated symptoms like itching and swelling. - **Panthenol** (provitamin B5) provides moisturizing and reparative effects on the mucosal surfaces and is intended to alleviate irritation and support healing. Primary indications include symptomatic relief of nasal congestion, allergic conditions of the nasal mucosa, and potentially for moisture support and irritation reduction in affected tissues. The combination has been studied in randomized clinical trials for the symptomatic control of nasal congestion, especially related to the common cold[2]. No unique branded product combining all three agents is documented in major drug databases, and this combination is likely regionally formulated or researched.

02

Targets

ADRA1A (α1A)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on naphazoline + pheniramine + panthenol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on naphazoline + pheniramine + panthenol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call